Gillingham Medical Centre – Library – Behind the Headlines

Gillingham Medical Centre - Library - Behind the Headlines

Stephen Porter is Director and Professor of Oral Medicine of UCL Eastman Dental Institute. I started writing this post, and then my laptop had a falling out with the wifi. Epstein Barr Virus Nhs Direct. He had a number of complex additional medical complications, is unable to communicate and was entirely dependent on his foster carer. This was a large trial examining the use of a new immune treatment called talimgogene laherparepvec (T-VEC) for advanced melanoma (the most serious type of skin cancer) that could not be removed surgically. T-VEC is a modified derivative of the herpes virus that causes cold sores. It is injected directly into the tumour and causes the production of a chemical called granulocyte-macrophage colony-stimulating factor (GM-CSF), which stimulates an immune response to fight the cancer.

It also improved overall survival, but this only just reached statistical significance, meaning we can have less confidence in this effect. Interestingly, most members of the herpesvirus family were found to express large numbers of their own sets of viral miRNAs (Table 1). While these results are encouraging, media claims of a cure for advanced melanoma are misguided. Further research is needed to see how T-VEC compares with existing treatments. Full information about gonorrhoea can be found on the NHS Choices website. The quality of the reporting of this study is somewhat patchy. The beads are made of a biocompatible material and measure only 0.5mm in size.

It recruits other white blood cells to fight infection or abnormal cells. Injecting a treatment that produces GM-CSF within a tumour should, in theory, boost the immune response to fight the tumour. He now takes Seth’s toys, and does not understand the rules of sharing. Don’t be the next at that point you simply can stop the herpes virus- how nhs direct genital herpes it because severe infection. This contrasts with the Official Solicitor’s usual role in Court of Protection proceedings, where he seeks to advance P’s best interests (rather than those of other Respondents to such proceedings). People were randomised to receive either T-VEC injections into the tumour or GM-CSF injections under the skin. Treatment was continued regardless of disease progression for 24 weeks, and after 24 weeks continued until there was disease progression, lack of response, remission or intolerability.
Gillingham Medical Centre - Library - Behind the Headlines

At one year, people with stable or responsive disease could continue for a further six months. The main outcome was disease response rate, defined as complete or partial response that started within the first 12 months and lasted continuously for at least six months. In addition, time-course analyses combined with computational modelling reveals the contribution of RNA processing and decay in these processes (Windhager et al., Genome Research 2012). Disease response rate was significantly better in people given T-VEC (16.3%) compared with those given GM-CSF (2.1%). This was an almost nine-fold increased odds of response (odds ratio [OR] 8.9, 95% confidence interval [CI] 2.7 to 29.2). Full information about genital warts can be found on the NHS Choices website. Average time to treatment failure was significantly longer in the T-VEC group (8.2 months) than in the GM-CSF group (2.9 months).

Average survival was 23.3 months with T-VEC, compared with 18.9 months with GM-CSF. Overall, this was a borderline significant reduction in risk of death, which included the possibility there was no difference (HR 0.79, 95% CI 0.62 to 1.00). Fatigue affected half of T-VEC treatment patients compared with just over a third in the GM-CSF group. A letter from our local Member of Parliament, and a second letter from the Prime Minister, David Cameron. Includes FAQ and membership details. It demonstrated that, overall, significantly more people responded to treatment with T-VEC than GM-CSF injections. It also improved survival by an average of 4.4 months, but this only just reached statistical significance, meaning we can have less confidence in this effect.

T-VEC boosts GM-CSF production within the tumour to enhance the immune response, and was therefore compared with GM-CSF injections. However, GM-CSF is not used as a treatment for advanced melanoma. Ideally, the treatment would need to be compared with treatments for advanced melanoma that are currently available – for example, chemotherapy, radiotherapy, and particularly other immune therapies, such as the antibody treatment ipilimumab. Epub 2012 Sep 6. Most of the people in this study passed away during the two years of follow-up, but the people receiving T-VEC generally lived slightly longer. The treatment is a genetically engineered derivative of herpes simplex type 1 virus. But this is not the same as having been infected with herpes simplex.

For example, people shouldn’t wrongly interpret the headlines to think getting cold sores offers protection against melanoma or other types of cancer. It is not known whether this treatment could only have potential for the treatment of advanced melanoma, or whether it could have other potential uses for other types of cancer. As with most conditions, prevention is more effective than cure when it comes to melanoma. Avoid overexposure to the sun or other artificial sources of ultraviolet light, such as sun beds, to reduce your risk of skin cancer.

You may also like